First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
This is an open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) and to determine the maximum tolerated dose (MTD) of STP1002 in patients with advanced-stage solid tumors.
Advanced Solid Tumor
DRUG: STP1002
Dose limiting toxicities (DLTs), DLTs are defined as any of the following adverse events (AEs) that are possibly or probably related to the trial regimen occurring during Cycle 1, 28 days
Treatment-emergent adverse events (TEAEs), Number and severity of TEAEs, treatment-related AEs, and SAEs for all dose groups according to the NCI CTCAE v5.0, 24 months|The pharmacokinetics of STP1002, Plasma concentration of STP1002 following oral administration, 24 months
This is an open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) and to determine the maximum tolerated dose (MTD) of STP1002 in patients with advanced-stage solid tumors.